Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

T-cell prolymphocytic leukemia.

Claire E Dearden¹

¹Department of Haemato-Oncology, The Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. claire.dearden@rmh.nhs.uk

Medical Oncology (Northwood, London, England)

|April 29, 2006

Summary

T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive cancer. Alemtuzumab therapy shows promising results in relapsed and untreated T-PLL patients, improving survival rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.

British journal of haematology·2018

Same author

Epidemiology and environmental aspects of marginal zone lymphomas.

Best practice & research. Clinical haematology·2017

Same author

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.

Leukemia & lymphoma·2016

Same author

Long-term follow-up after purine analogue therapy in hairy cell leukaemia.

Best practice & research. Clinical haematology·2015

Same author

An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy.

British journal of haematology·2015

Same author

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2014

Area of Science:

Hematology
Oncology
Immunology

Background:

T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy.
Conventional treatments offer limited efficacy and short survival for T-PLL patients.
Distinctive morphology, immunophenotype, and cytogenetics differentiate T-PLL from other T-cell leukemias.

Purpose of the Study:

To evaluate the efficacy of alemtuzumab in treating T-cell prolymphocytic leukemia.
To assess response rates and survival outcomes in T-PLL patients treated with alemtuzumab.
To explore future therapeutic strategies for T-PLL.

Main Methods:

Treatment of T-PLL patients with alemtuzumab, a CD52-targeted antibody.
Analysis of response rates (overall and complete) in relapsed/refractory and previously untreated patients.
Investigation of stem cell transplantation and combination therapies in ongoing clinical trials.

Main Results:

Alemtuzumab demonstrated high overall response rates (up to 76%) and complete response rates (up to 60%) in relapsed/refractory T-PLL.
Complete remission rates reached 100% in previously untreated T-PLL patients.
Observed durable responses translate into improved survival for T-PLL patients.

Conclusions:

Alemtuzumab is an effective targeted therapy for T-cell prolymphocytic leukemia.
Durable responses and improved survival are achievable with alemtuzumab treatment.
Ongoing research focuses on stem cell transplantation and combination therapies to further enhance T-PLL patient outcomes.

Related Experiment Videos